<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85781">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02053350</url>
  </required_header>
  <id_info>
    <org_study_id>UVaHS-144404</org_study_id>
    <nct_id>NCT02053350</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Alanyl-glutamine Supplementation for the Treatment of C. Difficile Infection</brief_title>
  <official_title>Alanyl-glutamine Supplementation of Standard Treatment of C. Difficile Infection in Patients With Malignancy: A Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the efficacy of alanyl-glutamine supplementation in the
      treatment of C. difficile infection.  We hypothesize that alanyl-glutamine when given with
      standard antibiotic treatment for C. difficile infection will decrease diarrhea, mortality
      and recurrent disease in patients with history of malignancy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to recurrent C. difficile infection</measure>
    <time_frame>Up to 6 months after enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of diarrhea</measure>
    <time_frame>Up to day 10 of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 6 months after enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Fecal lactoferrin</measure>
    <time_frame>Change in fecal lactoferrin from Day 0 to Days 5 and 10 of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Alanyl-glutamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alanyl-glutamine, 44g, taken by mouth daily  for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Glycine, 46g taken by mouth daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alanyl-glutamine</intervention_name>
    <arm_group_label>Alanyl-glutamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult of either gender, 18 years or older, with 1st episode C. difficile infection
             (CDI)

          -  Diarrhea associated with C. difficile positive stool assay

          -  Within 48 hours of receiving either metronidazole for mild-moderate disease or
             vancomycin for severe uncomplicated disease

          -  Concurrent or history of malignancy

          -  Admitted in the hospital at the time of enrollment

          -  Ability to provide informed consent

          -  Have an understanding of study procedures

          -  Ability to comply with study procedures for the entire length of the study

        Exclusion Criteria:

          -  Hypotension or shock

          -  Megacolon or moderate to severe ileus

          -  Acute abdomen

          -  Severe leukocytosis (WBC &gt; 20,000 cells /ÂµL)

          -  Admission to intensive care unit on enrollment

          -  Inability to tolerate oral medication

          -  Other known etiology of diarrhea (e.g. other enteric pathogen, other intestinal
             disease)

          -  Inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)

          -  Enrollment in another investigational drug trial

          -  Currently receiving other alternative treatment for CDI (e.g. antibiotics other than
             metronidazole or vancomycin; probiotics; immunoglobulin therapy; fecal transplant)

          -  History of multiple CDI

          -  Pregnancy

          -  Unavailable for follow-up visits

          -  Life expectancy of &lt; 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cirle A. Warren, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Chaplin, M.D.</last_name>
    <phone>434-283-3245</phone>
    <email>asc9h@virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cirle A Warren, M.D.</last_name>
      <phone>434-924-9676</phone>
      <email>ca6t@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Chaplin, M.D.</last_name>
      <phone>434-283-3245</phone>
      <email>asc9h@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cirle A. Warren, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Cirle Warren, MD</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Medicine, Infectious Disease</investigator_title>
  </responsible_party>
  <keyword>Clostridium difficile</keyword>
  <keyword>glutamine</keyword>
  <keyword>diarrhea</keyword>
  <keyword>alanyl-glutamine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
